Compare Neurocrine Biosciences Inc (NBIX) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Tempus AI — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Tempus AI trades at $49.05 (market cap $8.69B). The key difference: Neurocrine Biosciences Inc is far larger — about 2× Tempus AI's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| NBIX | TEM | |
|---|---|---|
Market Cap | $17.40B | $8.69B |
Sector | Health | Broad Market / Factor |
52-Week High | $180.55 | $103.25 |
52-Week Low | $123.10 | $42.37 |
Enterprise Value | $16.49B | $9.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
